🇺🇸 FDA
Pipeline program

rituximab

ANHL0221

Phase 2 mab completed

Quick answer

rituximab for Lymphoproliferative Disorder is a Phase 2 program (mab) at Children's Hospital of Fudan University with 1 ClinicalTrials.gov record(s).

Program details

Company
Children's Hospital of Fudan University
Indication
Lymphoproliferative Disorder
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials